PMID- 32590296
OWN - NLM
STAT- MEDLINE
DCOM- 20201230
LR  - 20211204
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 135
DP  - 2020 Aug
TI  - Quantitative and qualitative impairments in dendritic cell subsets of patients 
      with ovarian or prostate cancer.
PG  - 173-182
LID - S0959-8049(20)30240-9 [pii]
LID - 10.1016/j.ejca.2020.04.036 [doi]
AB  - BACKGROUND: Dendritic cells (DCs) are the most efficient antigen-presenting 
      cells, hence initiating a potent and cancer-specific immune response. This 
      ability (mainly using monocyte-derived DCs) has been exploited in vaccination 
      strategies for decades with limited clinical efficacy. Another alternative would 
      be the use of conventional DCs (cDCs) of which at least three subsets circulate 
      in human blood: cDC1s (CD141(bright)), cDC2s (CD1c(+)) and plasmacytoid DCs. 
      Despite their paucity, technical advances may allow for their selection and 
      clinical use. However, many assumptions concerning the DC subset biology depend 
      on observations from mouse models, hindering their translational potential. In 
      this study, we characterise human DCs in patients with ovarian cancer (OvC) or 
      prostate cancer (PrC). PATIENTS AND METHODS: Whole blood samples from patients 
      with OvC or PrC and healthy donors (HDs) were evaluated by flow cytometry for the 
      phenotypic and functional characterisation of DC subsets. RESULTS: In both 
      patient groups, the frequency of total CD141(+) DCs was lower than that in HDs, 
      but the cDC1 subset was only reduced in patients with OvC. CD141(+) DCs showed a 
      reduced response to the TLR3 agonist poly (I:C) in both groups of patients. An 
      inverse correlation between the frequency of cDC1s and CA125, the OvC tumour 
      burden marker, was observed. Consistently, high expression of CLEC9A in OvC 
      tissue (The Cancer Genome Atlas data set) indicated a better overall survival. 
      CONCLUSIONS: cDC1s are reduced in patients with OvC, and CD141(+) DCs are 
      quantitatively and qualitatively impaired in patients with OvC or PrC. CD141(+) 
      DC activation may predict functional impairment. The loss of cDC1s may be a bad 
      prognostic factor for patients with OvC.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Mastelic-Gavillet, Beatris
AU  - Mastelic-Gavillet B
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, 
      University of Lausanne, Lausanne, Switzerland.
FAU - Sarivalasis, Apostolos
AU  - Sarivalasis A
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland.
FAU - Lozano, Leyder Elena
AU  - Lozano LE
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, 
      University of Lausanne, Lausanne, Switzerland.
FAU - Wyss, Tania
AU  - Wyss T
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, 
      University of Lausanne, Lausanne, Switzerland; Bioinformatics Core Facility, 
      Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
FAU - Inoges, Susana
AU  - Inoges S
AD  - Division of Immunology and Immunotherapy, Center for Applied Medical Researckh, 
      University of Navarra, Pamplona, Spain; Instituto de Investigacion Sanitaria de 
      Navarra, Pamplona, Spain; University Clinic, University of Navarra, Pamplona, 
      Spain; Centro de Investigacion Biomedica en Red Cancer, Madrid, Spain.
FAU - de Vries, Ingrid Jolanda Monique
AU  - de Vries IJM
AD  - Department of Tumour Immunology, Radboud Institute of Molecular Life Sciences, 
      Geert Grooteplein 26-28, 6525 GA, Nijmegen, the Netherlands; Department of 
      Medical Oncology, Radboudumc, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, the 
      Netherlands.
FAU - Dartiguenave, Florence
AU  - Dartiguenave F
AD  - Urology Research Unit, Department of Urology, CHUV, Switzerland.
FAU - Jichlinski, Patrice
AU  - Jichlinski P
AD  - Urology Research Unit, Department of Urology, CHUV, Switzerland.
FAU - Derre, Laurent
AU  - Derre L
AD  - Urology Research Unit, Department of Urology, CHUV, Switzerland.
FAU - Coukos, George
AU  - Coukos G
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, 
      University of Lausanne, Lausanne, Switzerland.
FAU - Melero, Ignacio
AU  - Melero I
AD  - Division of Immunology and Immunotherapy, Center for Applied Medical Researckh, 
      University of Navarra, Pamplona, Spain; Instituto de Investigacion Sanitaria de 
      Navarra, Pamplona, Spain; University Clinic, University of Navarra, Pamplona, 
      Spain; Centro de Investigacion Biomedica en Red Cancer, Madrid, Spain.
FAU - Harari, Alexandre
AU  - Harari A
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, 
      University of Lausanne, Lausanne, Switzerland.
FAU - Romero, Pedro
AU  - Romero P
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, 
      University of Lausanne, Lausanne, Switzerland.
FAU - Vigano, Selena
AU  - Vigano S
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, 
      University of Lausanne, Lausanne, Switzerland. Electronic address: 
      selena.vigano@chuv.ch.
FAU - Kandalaft, Lana Elias
AU  - Kandalaft LE
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, 
      University of Lausanne, Lausanne, Switzerland. Electronic address: 
      lana.kandalaft@chuv.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Antigens, Surface)
RN  - 0 (CA-125 Antigen)
RN  - 0 (CLEC9a protein, human)
RN  - 0 (Lectins, C-Type)
RN  - 0 (MUC16 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Receptors, Mitogen)
RN  - 0 (THBD protein, human)
RN  - 0 (TLR3 protein, human)
RN  - 0 (Thrombomodulin)
RN  - 0 (Toll-Like Receptor 3)
RN  - O84C90HH2L (Poly I-C)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Surface/blood
MH  - CA-125 Antigen/blood
MH  - Case-Control Studies
MH  - Dendritic Cells/drug effects/*immunology
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunophenotyping
MH  - Lectins, C-Type/analysis
MH  - Male
MH  - Membrane Proteins/blood
MH  - Middle Aged
MH  - Ovarian Neoplasms/blood/*immunology/mortality
MH  - Phenotype
MH  - Poly I-C/pharmacology
MH  - Prognosis
MH  - Prostatic Neoplasms/blood/*immunology/mortality
MH  - Receptors, Mitogen/analysis
MH  - Thrombomodulin
MH  - Toll-Like Receptor 3/agonists
OTO - NOTNLM
OT  - CD141
OT  - Cross-presenting DC
OT  - Ovarian cancer
OT  - Prostate cancer
OT  - Vaccines
OT  - cDC1
COIS- Conflict of interest statement None declared.
EDAT- 2020/06/27 06:00
MHDA- 2020/12/31 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/12/31 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - S0959-8049(20)30240-9 [pii]
AID - 10.1016/j.ejca.2020.04.036 [doi]
PST - ppublish
SO  - Eur J Cancer. 2020 Aug;135:173-182. doi: 10.1016/j.ejca.2020.04.036. Epub 2020 
      Jun 23.